| Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway. | Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C, Yang M, Gu X, Gu Y., Free PMC Article | 01/22/2022 |
| LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway. | LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway.
Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N., Free PMC Article | 11/27/2021 |
| Our findings support a model in which the MIR2052HG regulates LMTK3 via EGR1, and LMTK3 regulates ERalpha stability via the PKC/MEK/ERK/RSK1 axis. These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERalpha-positive breast cancer. | The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J, Ingle JN, Kalari KR, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Wang L., Free PMC Article | 01/11/2020 |
| targeting of LMTK3 with siRNA delayed KIT-dependent GIST growth in a xenograft model. Our data suggest the potential of LMTK3 as a target for treatment of patients with KIT-mutant cancer, particularly after failure of KIT TKIs. | LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC., Free PMC Article | 03/9/2019 |
| LMTK3 expression and its role in the drug resistance in breast cancer. | LMTK3 confers chemo-resistance in breast cancer.
Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, Wendler F, Simon T, Szabó KS, O'Hanlon T, Dean M, Roslani AC, Cheah SH, Lee SC, Giamas G., Free PMC Article | 03/9/2019 |
| Phosphorylation of RCP at Ser(435) by Lemur tyrosine kinase-3 (LMTK3) and of EphA2 at Ser(897) by Akt are both necessary to promote Rab14-dependent (and Rab11-independent) trafficking of EphA2 which generates cell:cell repulsion events that drive tumour cells apart. | Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion.
Gundry C, Marco S, Rainero E, Miller B, Dornier E, Mitchell L, Caswell PT, Campbell AD, Hogeweg A, Sansom OJ, Morton JP, Norman JC., Free PMC Article | 11/10/2018 |
| LMTK-3 increased phosphorylated p38 and JNK, but decreased phosphorylated ERK1/2 and AKT. Overexpression of LMTKs may contribute to biologic behavior changes of PCa, especially cell apoptosis. | Lemur Tyrosine Kinase-3 Suppresses Growth of Prostate Cancer Via the AKT and MAPK Signaling Pathways.
Sun P, Sun X, Zhao W, Ren M, Zhang C, Wang Z, Xu W. | 11/18/2017 |
| The serum LMTK3 level was significantly increased in 102 thyroid carcinoma patients compared with 52 benign thyroid tumor patients and 50 healthy volunteers (P=0.001). The protein and mRNA expression of LMTK3 was markedly higher in thyroid cancer patients compared with patients with benign thyroid tumors. LMTK3 knockdown retarded proliferation, invasion and migration in SW579 cells. | LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer.
Lu L, Yuan X, Zhang Q, Zhang H, Shen B., Free PMC Article | 05/13/2017 |
| LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. | LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, Stebbing J, Giamas G. | 07/16/2016 |
| LMTK3 functions at distal regions in tethering the chromatin to the nuclear periphery, resulting in H3K9me3 modification and gene silencing. | LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer.
Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, Buluwela L, Magnani L, Stebbing J, Giamas G. | 05/14/2016 |
| The serum LMTK3 level was significantly increased in human non-small cell lung cancer, and could be used as a potential and valuable biomarker | Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
Zhang K, Chen L, Deng H, Zou Y, Liu J, Shi H, Xu B, Lu M, Li C, Jiang J, Wang Z., Free PMC Article | 12/12/2015 |
| abundance of LMTK3 positively correlated with that of the integrin beta1 subunit in breast cancer patient's tumors | The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁.
Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G. | 02/7/2015 |
| Results show that high expression of LMTK3 is an independent prognostic factor in estrogen receptor alpha-positive breast cancer patients receiving adjuvant endocrine therapy | High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Y, Takahashi S, Fujii Y, Toyama T. | 01/3/2015 |
| LMTK3 expression was an independent prognostic factor for colorectal cancer patients | Lemur tyrosine kinase-3 is a significant prognostic marker for patients with colorectal cancer.
Shi H, Li Q, Ji M, Wu J, Li Z, Zheng X, Xu B, Chen L, Li X, Lu C, Tan Y, Wu C, Jiang J., Free PMC Article | 12/20/2014 |
| These computational reports provide more information on the structure-function relationship of LMTK3 with ATP. | Structural modeling and molecular dynamics studies on the human LMTK3 domain and the mechanism of ATP binding.
Anbarasu K, Jayanthi S. | 11/22/2014 |
| Kaplan-Meier survival curves showed that colorectal cancer patients with high levels of sLMTK3 had a poorer overall survival rate when compared with those of patients with low levels of sLMTK3. | Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis.
Shi H, Wu J, Ji M, Zhou Q, Li Z, Zheng X, Xu B, Deng H, Zhao W, Wu C, Jiang J. | 07/19/2014 |
| harboring rs8108419 G/G genotype of the LMTK3 was associated with OS in the Japanese females (HR, 3.04; 95% CI, 1.08-8.56; P = 0.035) and the U.S. males (HR, 3.39; 95% CI, 1.31-8.80; P = 0.012). | Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.
Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ., Free PMC Article | 05/24/2014 |
| miR-34a inhibits breast cancer proliferation by targeting LMTK3 | MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.
Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z, Cong X., Free PMC Article | 02/1/2014 |
| role for LMTK3 in both innate (intrinsic) and acquired (adaptive) endocrine resistance in breast cancer | LMTK3 is implicated in endocrine resistance via multiple signaling pathways.
Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G. | 09/14/2013 |
| Higher LMTK3 expression is associated with more aggressive breast cancers. | LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome.
Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC, Giamas G. | 06/23/2012 |
| abundance and intronic polymorphism associated with breast cancer survival and response to endocrine therapies | Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.
Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J. | 08/20/2011 |